T cell activation requires a T cell receptor (TCR) to recognize its cognate peptide in the context of an MHC molecule. In addition, the association of CD3 with the TCR–peptide–MHC complex ...

Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer ...

ACROBiosystems CD3 molecules tend to bind to TCR non-covalently to develop a TCR/CD3 receptor complex on the T-cell’s surface. There are four subtypes of CD3 — CD3ε, CD3δ, CD3γ and CD3ζ.

Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of ...

and the CD3 receptor, which is expressed on the surface of healthy T-cells. The latest pre-clinical R&D update expands the biotech's reach. In July 2015, Immunocore secured $320 million in ...

Scientists have engineered CAR-T cells with on/off switches activated by existing drugs, enhancing safety in cancer therapy.

that consists of a soluble TCR targeting gp100 expressed on cancer cells fused to a protein that binds CD3 receptors on lymphocytes – as a treatment for unresectable or metastatic uveal melanoma.

(NASDAQ:AMGN) are developing CX-904, a T-cell-engaging bispecific Probody candidate against the epidermal growth factor receptor (EGFR) on cancer cells and the CD3 receptor on T cells. The drug ...

This important study provides solid in-vivo evidence that CCR4 regulates the early inflammatory response during atherosclerotic plaque formation. The authors propose that altered T-cell response plays ...

This valuable study reports on a novel role of PD-1 in early T cell differentiation, showing that PD-1 stimulation impairs Th2 differentiation more effectively than that of Th1, with implications for ...